Advice
Following an abbreviated submission.
Pioglitazone 15mg/metformin 850m g hydrochloride (Competact) is accepted for restricted use in NHSScotland for the treatment of type 2 diabetes mellitus. It should be used for overweight patients who are unable to achieve sufficient glycaemic control at their maximally tolerated doses of oral metformin alone. It is restricted to patients who cannot be treated with a sulphonylurea in combination with metformin.
This combination product costs the same as equivalent doses of the individual constituent preparations and offers a more convenient, though less flexible, dosing regimen.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Pioglitazone 15mg/metformin 850mg hydrochloride (Competact)
- SMC ID:
- 252/06
- Indication:
- Type 2 diabetes mellitus
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 September 2006